View Older Stories View More Recent Stories
-
Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly plans $6 billion Alabama manufacturing facility
-
Lilly completes Adverum acquisition for $3.56 per share plus CVRs
-
Lilly's Jaypirca reduces cancer progression risk by 80% in study
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Nobel laureate Carolyn Bertozzi rejoins Eli Lilly board
-
Eli Lilly (LLY) PT Raised to $1,200 at BMO Capital
-
Eli Lilly (LLY) PT Raised to $1,163 at Guggenheim
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $950 at Berenberg
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $1,286 at BofA Securities, 'Remains in the GLP1 driver's seat'
-
Eli Lilly reduces Zepbound prices on direct platform
-
Eli Lilly's (LLY) Zepbound Reached All-Time High on TRx and NRx- Cantor Fitzgerald
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Bernstein on IRA pricing: $245 really is the floor
-
Lilly to present breast cancer drug trial results at December symposium
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Eli Lilly (LLY) PT Raised at Bernstein on 'An Incredibly Rich Catalyst Path Ahead'
-
Eli Lilly (LLY) PT Raised to $1,290 at Morgan Stanley
-
Lilly elects Stanford chemistry professor to board of directors
-
Eli Lilly joins $1 trillion club as weight-loss drugs fuel growth
-
Eli Lilly & Co. (LLY) passes $1 trillion in market cap
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
Breakthrough Properties partners with Eli Lilly for Philadelphia lab space
-
Lilly to open Gateway Labs site in Philadelphia
-
Eli Lilly (LLY) PT Raised to $1,182 at Truist Securities
-
Eli Lilly (LLY) PT Raised to $1,150 at JPMorgan on Growth Potential in 2026+
-
Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
-
MeiraGTx Holdings plc (MGTX) PT Raised at RBC Capital Amid LLY Deal
-
Mangoceuticals clarifies GLP-1 weight-management program launch
-
Lilly and Novo Nordisk say no affiliation with Mangoceuticals (MGRX)
-
Eli Lilly (LLY) PT Raised to $1,500 at Citi
-
Freedom Capital Markets Downgrades Eli Lilly (LLY) to Hold
-
Eli Lilly upgraded at Leerink on 'multiple waves' of obesity drug adoption
-
Leerink Partners Upgrades Eli Lilly (LLY) to Outperform
-
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY) Post US Government Deal
-
Lilly names new executives to lead neuroscience and immunology units
-
Eli Lilly agrees with government to cap obesity drug costs at $50 monthly
-
Trump administration reaches GLP-1 drug pricing deals with Eli Lilly and Novo Nordisk - White House
-
Eli Lilly & Co. (LLY) call put ratio 3.1 calls to 1 put with a focus on November 7 weekly calls
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put amid price movement
-
Stocks expected to have increasing option volume: LLY NVO VKTX NVAX ARM QCOM LYFT APP HOOD DASH MCK TKO AZN ABNB SNAP VST
-
Eli Lilly (LLY) PT Raised to $1,100 at BMO Capital
-
Deutsche Bank: 'We think the pricing overhangs for GLP1s look relatively benign and favorable to LLY'
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Trump admin talking to Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumpRx - WSJ
-
Lilly and Novo near White House deal on obesity drug prices - Endpoints News
